Evolution and regional disparities in guideline recommendations and evidence levels for structural heart disease

Area of Science:

• Cardiology
• Clinical Guidelines
• Evidence-Based Medicine

Background:

• Structural heart disease (SHD) management has advanced significantly.
• The characteristics and evolution of SHD guidelines across different regions are not well understood.
• Assessing guideline quality and regional variations is crucial for improving patient care.

Purpose of the Study:

• To analyze the distribution of recommendation classes and levels of evidence (LOE) in SHD guidelines.
• To compare these characteristics across the American College of Cardiology/American Heart Association (ACC/AHA), European Society of Cardiology (ESC), and Chinese cardiovascular societies.
• To evaluate the evolution of evidence quality in SHD guidelines over time.

Main Methods:

• Systematic evaluation of 1,867 recommendations from prior and current SHD guidelines.
• Categorization of recommendations by class (strength) and level of evidence (LOE A, B, C).
• Comparative analysis of guideline data across ACC/AHA, ESC, and Chinese societies.

Main Results:

• In current guidelines, 53.2% of recommendations were strong (Class I/III), but only 8.1% had the highest LOE A.
• Regional variations were observed: ACC/AHA guidelines predominantly used LOE B (56.3%), while ESC and Chinese guidelines relied heavily on LOE C (79.4% and 69.5%, respectively).
• Longitudinal analysis indicated an overall improvement in the quality of evidence supporting recommendations.

Conclusions:

• A persistent challenge exists in aligning the strength of recommendations with the quality of supporting evidence in SHD guidelines.
• Significant regional disparities in evidence utilization necessitate international collaboration for guideline development.
• Enhancing evidence quality and standardizing guideline development processes globally are essential for optimal SHD management.